

Study of Platelet and Endothelial Microparticles in Patients with Type 2 Diabetes Mellitus

THESIS

Submitted in partial fulfillment

For M.Sc. Degree

“Clinical and Chemical Pathology Department”

BY

Alaa Amr Gad

M.B.B.Ch

SUPERVISED BY

Prof. Dr. Azza Mostafa

Prof.Dr. Eman Mansour

Professor of Clinical Pathology

Professor of Clinical Pathology

Faculty of Medicine

Faculty of Medicine

Cairo University

Cairo University

Prof.Dr.Ibrahim El Abrashy

Professor of Internal Medicine

Faculty of Medicine

Cairo University

2010

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا هَا
عَلَّمْتَنَا^ط

إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

البقرة (32)

ACKNOWLEDGEMENT

In the Name of Allah, the Beneficent, the Merciful

*First praise is to **Allah**, the Almighty, on whom ultimately we depend for sustenance and guidance.*

*I especially want to thank **Dr Azza Mostafa** ,Professor of clinical pathology , Faculty of Medicine , Cairo university for her guidance during my study , Her perpetual energy , enthusiasm and paramount mentorship in research had motivated all her advisees, including me.*

*I would like to express my deepest sense of gratitude to **Dr. Eman Mansour** , Professor of clinical pathology , Faculty of medicine , Cairo university for her patient guidance, encouragement and excellent advice throughout this study. It's been a privilege to work under her supervision .*

*I greatly acknowledge **Dr. Ibrahim El Ebrashy** , Professor of Internal medicine , Faculty of medicine , Cairo University , for his advice and crucial contribution which made him the backbone of this thesis .*

*My sincere appreciation goes to my supervisor **Dr. Hanan El Husseiny** , lecturer of clinical pathology , Faculty of medicine ,Cairo university whose guidance, careful reading and constructive comments were valuable. Her timely and efficient contribution helped me shape this into its final form.*

*Words are not enough to express my gratitude to **Dr. Eman William** , Assistant professor of haematology , Theodor Bilharz research Institute whose cooperation and great effort in the practical part of thesis had helped me throughout my study .*

*I owe my most sincere gratitude to **my family** for their unconditional love and support throughout my life; this dissertation is simply impossible without them, I have no suitable word that can fully describe my everlasting love to them.*

*And last but not the least, I would like to thanks all my **friends** and **colleagues** who supported me and gave me confidence.*

TABLE OF CONTENT

I- Introduction and aim of work.....	1
II- Review of literature.....	4
<u>Chapter 1: Microparticles</u>	
*Plasma membrane remodeling and microparticle formation	6
*Structure of cellular microparticles.....	10
*Cellular origin of microparticles:	
a -Platelet derived microparticles.....	13
b -Endothelial derived microparticles	14
i- EMP in healthy conditions.....	14
ii- Characterization.....	15
iii- Generation and release.....	16
c-Leucocyte derived microparticles.....	18
i- Monocyte derived microparticles.....	18
ii- Polymorphonuclear derived microparticles	19
d-Erythrocyte derived microparticles.....	19
*Membrane microparticles in intercellular communication.....	21
*Biological effects of microparticles:	
a -Microparticles and thrombus formation.....	24
b -Microparticles and inflammation.....	26
c-Microparticles and vascular formation.....	28
d-Microparticles and angiogenesis	31

***Patho-physiologic significance of platelet and endothelial microparticles.**

a-Microparticles in systemic disease.....	35
b-Microparticles in cardiovascular disease.....	35
i - Deep vein thrombosis and pulmonary embolism.....	36
ii – Stroke.....	37
iii-Peripheral vascular disease.....	37
iv-Coronary artery syndrome.....	37
c-Microparticles in sickle cell disease.....	38
d-Microparticles in sepsis.....	39
f-Microparticles in thrombotic thrombocytopenic purpura.....	42
g-Microparticles in paroxysmal nocturnal haemoglobinuria.....	42

Chapter 2: Diabetes Mellitus

*Definition and Description of Diabetes Mellitus.....	43
*Classification of Diabetes Mellitus.....	47
a-Type 1 diabetes.....	47
b-Type 2 diabetes.....	49
c-Other specific types of diabetes.....	51
i-Genetic defect of the B cell.....	51
ii-Genetic defect in insulin action.....	51
iii-Diseases of the exocrine pancreas.....	51
iv-Endocrinopathies.....	52
v-Drug or chemical induced diabetes.....	52
vi-Infections.....	52
vii-Other genetic syndromes sometimes associated with diabetes.....	53
viii-Gestational diabetes.....	53
ix-Impaired Glucose tolerance and impaired fasting glucose.....	53

*Vascular complication of Diabetes Mellitus.....	54
*Platelet activation and type 2 Diabetes.....	56
*Endothelial dysfunction and type 2 Diabetes.....	59
*MPs as markers in diabetes.....	61
*MPs :biological effectors in diabetes.....	63
*MPs and prevention of diabetic complications.....	66
 III - Subjects and methods.....	 67
IV – Results.....	79
V - Discussion.....	118
VI – Summary.....	131
VII- References.....	133
VI – Arabic summary.....	1

List of abbreviations

- **APC**: Activated Protein C
- **AT-II** : Angiotensin-II
- **ATP** : Adenosine Triphosphate
- **BFGF** : Basic Fibroblast Growth Factor
- **CA²⁺** : Calcium
- **CABG** : Coronary artery bypass graft
- **CAD** : Coronary Artery Disease
- **CD** : Cluster Of Differentiation
- **CGMP** : Cyclic guanosine monophosphate
- **COX** : Cyclooxygenase
- **CVD** : Cardio Vascular Disease
- **DM** : Diabetes Mellitus
- **EGF**: Endothelial growth factor
- **ELISA**: Enzyme linked immunosorbant assay
- **EMPs** : Endothelial microparticles
- **EPC** : Endothelial progenitor cell
- **EPCR**: Endothelial protein C receptor
- **ERK** : Extracellular Regulated Kinase
- **ET-1** : Endothelin-1
- **FAS** : Fatty acid synthase
- **FASL** : FAS ligand
- **GAD** :Glutamate decarboxylase

- **GDM** : Gestational Diabetes Mellitus
- **GP** : Glycoprotein
- **GPI**: Glycoprotein I
- **HBA1c** : Glycosylated hemoglobin
- **HDL** : High Density Lipoprotein
- **HLA** : Human Leucocytic Antigen
- **ICAM** : Intercellular adhesion molecule
- **IDDM** : Insulin Dependant Diabetes Mellitus
- **IFG** : Impaired Fasting Glucose
- **IGT** : Impaired Glucose Tolerance
- **ILs**: Interleukins
- **LASER** : Light Amplification by Stimulated Emission of Radiation
- **LDL** : Low Density Lipoprotein
- **LPS** : Lipopolysaccharide
- **MAC-1** : Macrophage -1 antigen
- **MDMP**: Monocyte derived microparticles
- **MHC**: Major histocompatibility complex
- **Min** : Minute
- **MMPs** : Monocyte microparticles
- **MODY** : Maturity Onset Diabetes of the Young
- **MPs** : Microparticles
- **NFκB** :Nuclear Factor Kappa-light-chain enhancer of activated B cells
- **NO** : Nitric oxide
- **NOS** : Nitric oxid synthase

- **OGTT**: Oral glucose tolerance test
- **PAF** : Platelet activated factor
- **PAR**: Protease activated receptor
- **PDGF** : Platelet Derived Growth Factor
- **PDMPs** : Platelet derived microparticles
- **PE** : Phosphatidyl-ethanolamine
- **PECAM** : Platelet-endothelial cell adhesion molecule
- **PF4** : Platelet Factor 4
- **PGI-2** : Prostacyclin
- **PI** : Phosphatidyl inositol
- **PI-3** : Phosphoinositide-3
- **PL** : Phospholipid
- **PLA2** : Phospholipase A2
- **PMA** : Phorbol 12-myristate 13-acetate
- **PMNs** : Polymorphonuclear leucocyte
- **PMPs** : Platelet microparticles
- **PMT** : Photomultiplier
- **PNH** : Paroxysmal Nocturnal Hemoglobinuria
- **PPP** : Platelet Poor Plasma
- **PRP** : Platelet Rich Plasma
- **PS** : Phosphatidylserine
- **PSGL** : P-selectin glycoprotein ligand
- **Ptdsr** : Phosphatidylserine receptor

- **RANTES** : Regulated upon Activation , Normal T cell Expressed and Secreted
- **RhAPC**: Recombinant human activated ptn C
- **ROS** : Reactive Oxygen Species
- **RPM** : Rotation Per Minute
- **SCD** : Sickle Cell Disease
- **T2DM** : Type 2 Diabetes Mellitus
- **TACE**: Tumor necrosis factor α converting enzyme
- **TF** : Tissue factor
- **TNF**: Tumor necrosis factor
- **TTP** : Thrombotic Thrombocytopenic Purpura
- **TXA2** : Thromboxane A2
- **VCAM** : Vascular cell adhesion molecule
- **VEGF** : Vascular Endothelial Growth Factor
- **vWF** : von Willebrand factor

List of Figures

Fig(1):Cellular MP: a disseminated storage pool of bioactive effectors.....	5
Fig(2): Maintenance of the asymmetric distribution of phospholipids in the membrane by a three piece enzyme system.....	7
Fig(3):Microparticle formation.....	9
Fig(4):Schematic representation of microparticle generation and composition.....	10
Fig(5):Formation of phenotypically heterogenous microparticles.....	13
Fig(6):Paracrine effects of endothelial microparticles.....	17
Fig(7):Platelet-Leucocyte-Endothelial Crosstalk.....	23
Fig(8):Microparticles and atherosclerotic plaque progression.....	27
Fig(9): Differential effects of microparticles on angiogenesis depending on their origin.....	33
fig(10): Microparticles evoked effects in the vascular system depending on their cellular origin.....	36
Fig(11):Role of circulating endothelial and PMN leucocyte derived microparticles in sepsis.....	40
Fig(12): Role of Endothelial-derived microparticles during sepsis.....	41
Fig(13):Disorders of glycemia , etiologic types and stages.....	45

Fig(14):MPs and their biological effects in diabetes.....	65
Fig (15) :Flow cytometry results	107
Fig (16):HbA1c level in the studied groups.....	108
Fig (17) :Cholesterol level in the studied groups.....	109
Fig(18):HDL level in the studied groups.....	109
Fig (19):LDL level in the studied groups.....	110
Fig (20) :Chol/HDL ratio in the studied groups.....	110
Fig (21) : LDL/HDL levels in the studied groups.....	111
Fig (22) : CD31+/CD42b+ in the studied groups.....	112
Fig (23) : CD62P in the studied groups.....	112
Fig (24) : CD31+/CD42b- in the studied groups.....	113
Fig (25) : CD62E in the studied groups.....	113
Fig (26) : CD62/CD31+,CD42- in the studied groups.....	114
Fig (27) : Correlation between CD62E and HbA1c	115
Fig (28) : correlation between LDL and CD31+/CD42b-.....	116
Fig (29): Correlation between CD62P and CD62E.....	117

List of tables

Table (1) : Markers for cell-derived microparticles.....	20
Table (2) : Effects of microparticles on the vascular tone.....	30
Table (3) : Demographic data of the studied groups.....	89
Table (4) : Clinical findings of the studied groups	89
Table (5) : Hb , WBCs and Platelet count in the control groups.....	90
Table (6) : Hb , WBCs and Platelet count in Group I.....	91
Table (7) : Hb , WBCs and Platelet count in Group II.....	92
Table (8) : Fasting glucose level in the studied groups.....	93
Table (9) : Hb A1c levels in the studied groups.....	94
Table(10):The statistical comparative study of FBS and HbA1c.....	95
Table (11) : Lipid profile results of controls.....	96
Table (12) :Lipid profile in Group I.....	97
Table (13) : Lipid profile of Group II.....	98
Table (14) : The statistical comparative study of the lipid profile and high risk ratio among the studied groups.....	99
Table(15):Platelet microparticles measured by CD42b + / CD 31+.....	100

Table (16) :Platelet microparticles measured by CD 62 P.....	101
Table (17) : Endothelial microparticles measured by CD31 + / CD42-	102
Table (18) : Endothelial microparticles measured by CD 62 E	103
Table (19) :CD62E / CD31 Ratio in the studied groups.....	104
Table (20) : The statistical comparative study of PMPs and EMPs	105
Table (21) : The statistical comparative study of PMPs and EMPs	106